Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Did Breast Cancer Radiation Cause This Weird Lung Problem?

2.

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

3.

How wildfires pose challenges to cancer care

4.

Psychotropics Linked to Increased BMI, CVD Risk

5.

Why breast cancer survivors don't take their medicine, and what can be done about it.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot